Is urinary D-arabinitol a marker for invasive candidiasis?

Invasive candidiasis is a life-threatening opportunistic infection, particularly in critically ill or immunocompromised patients. Rapid diagnostic tools are vital for improving outcomes, and detecting unique fungal metabolites like D-arabinitol (DA) offers a non-invasive diagnostic pathway.

Pathophysiological and metabolic mechanisms

• Fungal Biosynthesis: Pathogenic Candida species (such as Candida albicans) synthesize D-arabinitol via the pentose phosphate pathway. The intermediate D-ribulose-5-phosphate is dephosphorylated to D-ribulose, which is then reduced to D-arabinitol by an NAD-dependent D-arabitol dehydrogenase (ArDH) encoded by the ARD gene.
• Stereoselective Difference: Humans exclusively produce the L-enantiomer (L-arabinitol), while Candida synthesizes the D-enantiomer. This stereochemical divergence allows clinicians to measure the D/L-arabinitol ratio to isolate and quantify host fungal load.

Clinical efficacy and diagnostic value

• Diagnostic Performance: Elevated urinary D-arabinitol—measured either as a D/L ratio or adjusted for creatinine (DA/Cr ratio)—correlates with disseminated disease. In high-risk cohorts, such as neutropenic pediatric patients, urine D/L ratio assays have achieved diagnostic sensitivities up to 100%.
• Fungal Burden Monitoring: Because Candida actively secretes DA during proliferation, urinary levels correspond with systemic fungal burden, reflecting active fungal growth rather than static cellular antigens.

Clinical limitations and considerations

• Diagnostic Accuracy: Across broad adult populations, the sensitivity of the DA/Cr ratio ranges from 50% to 80%, with a specificity of 70% to 90%. Consequently, a negative result cannot confidently rule out systemic infection.
• Renal Dysfunction: Because DA is cleared renally, impaired kidney function is a major clinical confounder that can artificially elevate the D/L or DA/Cr ratios, resulting in false-positive diagnostic readings.

Bottom line

• Urinary D-arabinitol is a biochemically sound, non-invasive biomarker for invasive candidiasis, though its clinical interpretation must account for patient renal function and is best integrated into composite diagnostic panels.